Moderna (MRNA) Completes Submission of BLA to U.S. Food and Drug Administration for its COVID-19 Vaccine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. USO
7. APGE
8. ABBV
9. DFTX
10. MSFT

Go back to Moderna (MRNA) Completes Submission of BLA to U.S. Food and Drug Administration for its COVID-19 Vaccine

Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

August 25, 2021 9:44 AM EDT

Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has... More